{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:35:23Z","timestamp":1780976123405,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.02.030","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T22:55:58Z","timestamp":1709506558000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study"],"prefix":"10.1016","volume":"236","author":[{"given":"Ying X.","family":"Gue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Memtsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim","family":"Kanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wellsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Busby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisdair","family":"Ryding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa J.","family":"Arachchillage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.thromres.2024.02.030_bb0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2015.02.040","article-title":"Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk","volume":"65","author":"Okafor","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.thromres.2024.02.030_bb0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.030_bb0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.030_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.030_bb0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2019.07.030","article-title":"Impaired spontaneous\/endogenous fibrinolytic status as new cardiovascular risk factor?: JACC review topic of the week","volume":"74","author":"Gorog","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.thromres.2024.02.030_bb0030","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.thromres.2024.02.030_bb0035","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.030_bb0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.thromres.2024.02.030_bb0045","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","article-title":"Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction","volume":"44","author":"Lee","year":"2023","journal-title":"Eur. Heart J."},{"issue":"13","key":"10.1016\/j.thromres.2024.02.030_bb0050","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.030_bb0055","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007754","article-title":"More, more, more: reducing thrombosis in acute coronary syndromes beyond dual antiplatelet therapy-current data and future directions","volume":"7","author":"Spinthakis","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.030_bb0060","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/jcm10050929","article-title":"Precision treatment in ACS-role of assessing fibrinolysis","volume":"10","author":"Gue","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.030_bb0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11239-019-02014-5","volume":"49","author":"Gue","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"38","key":"10.1016\/j.thromres.2024.02.030_bb0070","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.030_bb0075","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.030_bb0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehs300","article-title":"Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease","volume":"34","author":"Sharma","year":"2013","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.030_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2257.2005.00681.x","article-title":"Thrombelastography\/thromboelastometry","volume":"27","author":"Luddington","year":"2005","journal-title":"Clin. Lab. Haematol."},{"issue":"23","key":"10.1016\/j.thromres.2024.02.030_bb0090","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.02.030_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.11.023","article-title":"Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis","volume":"173","author":"Spinthakis","year":"2019","journal-title":"Thromb. Res."},{"issue":"19","key":"10.1016\/j.thromres.2024.02.030_bb0100","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.jacc.2023.03.388","article-title":"Biomarkers of thrombotic status predict spontaneous reperfusion in patients with ST-segment elevation myocardial infarction","volume":"81","author":"Kanji","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.030_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","article-title":"Thrombin generation and fibrin clot structure","volume":"21","author":"Wolberg","year":"2007","journal-title":"Blood Rev."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.030_bb0110","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/jth.13441","article-title":"Coagulation and non-coagulation effects of thrombin","volume":"14","author":"Posma","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.030_bb0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/09537104.2016.1158402","article-title":"Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation","volume":"27","author":"Farag","year":"2016","journal-title":"Platelets"},{"issue":"9","key":"10.1016\/j.thromres.2024.02.030_bb0120","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/europace\/euz176","article-title":"Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation","volume":"21","author":"Spinthakis","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.thromres.2024.02.030_bb0125","doi-asserted-by":"crossref","first-page":"991675","DOI":"10.3389\/fcvm.2022.991675","article-title":"The impact of direct oral anticoagulants on viscoelastic testing - a systematic review","volume":"9","author":"Sahli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.030_bb0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.030_bb0135","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1055\/a-1730-8725","article-title":"Pharmacodynamic profiles of dual-pathway inhibition with or without Clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease","volume":"122","author":"Galli","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.02.030_bb0140","article-title":"Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) study","volume":"12","author":"Ortega-Paz","year":"2023","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2024.02.030_bb0145","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvac022","article-title":"Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy","volume":"8","author":"Galli","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"11","key":"10.1016\/j.thromres.2024.02.030_bb0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jacbts.2022.05.007","article-title":"Determinants of endogenous fibrinolysis in whole blood under high shear in patients with myocardial infarction","volume":"7","author":"Kanji","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"issue":"6","key":"10.1016\/j.thromres.2024.02.030_bb0155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2017013573","article-title":"Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction","volume":"2","author":"Borst","year":"2018","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.thromres.2024.02.030_bb0160","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11239-017-1495-z","article-title":"Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation","volume":"43","author":"Steppich","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"8","key":"10.1016\/j.thromres.2024.02.030_bb0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.thromres.2024.02.030_bb0170","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.02.030_bb0175","author":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI - PubMed [Internet]"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.030_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.thromres.2024.02.030_bb0185","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:19:04Z","timestamp":1717251544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":37,"alternative-id":["S0049384824000720"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.030","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}